New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management

Core Insights - New clinical and real-world data presented at ACC.26 reinforce the benefits of Vutrisiran for patients with ATTR-CM and highlight the potential of Zilebesiran for hypertension management [1][2][3] Vutrisiran Insights - Vutrisiran is the first and only TTR silencer that provides rapid knockdown of TTR at the source, showing significant improvements in health-related quality of life (QoL) for ATTR-CM patients, with effects comparable to those in patients over ten years younger [2][5][6] - The HELIOS-B analyses indicate that Vutrisiran leads to sustained benefits across various disease severities, demonstrating a 40% reduction in the risk of all-cause mortality and recurrent cardiovascular events in patients with advanced disease compared to placebo [7][8] - Real-world data show a high adherence rate of 93.8% among patients receiving Vutrisiran, with most patients continuing treatment after 12 months [8] Zilebesiran Insights - Zilebesiran is an investigational RNAi therapeutic aimed at reducing cardiovascular risk in patients with hypertension, showing a favorable safety profile in Phase 2 studies [3][11] - The ongoing ZENITH Phase 3 trial aims to evaluate Zilebesiran's efficacy in providing continuous blood pressure control, targeting angiotensinogen to manage hypertension effectively [10][17] Safety and Efficacy Data - Pooled safety data from Phase 2 studies indicate that Zilebesiran has an acceptable safety profile, with low incidences of clinically relevant safety events such as hypotension and hyperkalemia [11] - Vutrisiran's safety profile remains favorable, with no new safety issues identified in patients with advanced disease [15]